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Osteoclasts are responsible for bone resorption, 
and thereby play an essential role in maintain­
ing  bone  volume  and  homeostasis  (Karsenty 
and Wagner, 2002). Dysregulation of osteoclast 
differentiation or function disrupts mainte­
nance of bone homeostasis, which in turn leads 
to pathogenic conditions such as osteoporosis, 
rheumatoid  arthritis,  lytic  bone  metastases, 
or Paget’s bone disease (Rodan and Martin, 
2000). Thus, osteoclasts could potentially be 
targeted therapeutically to treat skeletal disor­
ders. Osteoclasts originate from BM–derived 
monocyte/macrophage precursor cells of hema­
topoietic origin and are differentiated by sig­
naling through the receptor activator of NF­B 
ligand (RANKL; Kong et al., 1999). RANKL 
induces osteoclast differentiation by activating 
the nuclear factor of activated T cells 1 (NFATc1), 
CORRESPONDENCE  
Takeshi Miyamoto: 
miyamoto@sc.itc.keio.ac.jp
Abbreviations used: Bcl6, B cell 
lymphoma 6; Blimp1, B  
lymphocyte–induced maturation 
protein 1; BMM, BM macro­
phage; ChIP, chromatin  
immunoprecipitation; cKO, 
conditional KO; Ctsk, cathepsin 
K; DC­STAMP, DC­specific 
transmembrane protein; DKO, 
double KO; NFATc1, nuclear 
factor of activated T cells 1; 
PGC, primordial germ cell; 
RANKL, receptor activator of 
NF­B ligand; TRAP, tartrate­
resistant acid phosphatase.
Y. Miyauchi and K. Ninomiya contributed equally to this 
paper.
The Blimp1–Bcl6 axis is critical  
to regulate osteoclast differentiation  
and bone homeostasis
Yoshiteru Miyauchi,1 Ken Ninomiya,1 Hiroya Miyamoto,1  
Akemi Sakamoto,6 Ryotaro Iwasaki,3 Hiroko Hoshi,1 Kana Miyamoto,1  
Wu Hao,1 Shigeyuki Yoshida,3 Hideo Morioka,1 Kazuhiro Chiba,1  
Shigeaki Kato,7 Takeshi Tokuhisa,6 Mitinori Saitou,8 Yoshiaki Toyama,1 
Toshio Suda,4 and Takeshi Miyamoto1,2,5,9
1Department of Orthopedic Surgery, 2Department of Integrated Bone Metabolism and Immunology, 3Department of Dentistry 
and Oral Surgery, 4Department of Cell Differentiation, The Sakaguchi Laboratory of Developmental Biology, 5Keio Kanrinmaru 
Project, Keio University School of Medicine, Shinjuku-ku, Tokyo 160-8582, Japan
6Department of Developmental Genetics, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan
7Institute of Molecular and Cellular Bioscience, University of Tokyo, Bunkyo-ku, Tokyo 113-0032, Japan
8Department of Anatomy and Cell Biology, Graduate School of Medicine, Kyoto University, Yoshida-Konoe-cho,  
Sakyo-ku, Kyoto 606-8501, Japan
9Precursory Research for Embryonic Science and Technology, Japan Science and Technology Agency, Kawaguchi,  
Saitama 332-0012, Japan
Controlling osteoclastogenesis is critical to maintain physiological bone homeostasis and 
prevent skeletal disorders. Although signaling activating nuclear factor of activated T cells 
1 (NFATc1), a transcription factor essential for osteoclastogenesis, has been intensively 
investigated, factors antagonistic to NFATc1 in osteoclasts have not been characterized. 
Here, we describe a novel pathway that maintains bone homeostasis via two transcriptional 
repressors, B cell lymphoma 6 (Bcl6) and B lymphocyte–induced maturation protein-1 
(Blimp1). We show that Bcl6 directly targets ‘osteoclastic’ molecules such as NFATc1, 
cathepsin K, and dendritic cell-specific transmembrane protein (DC-STAMP), all of which 
are targets of NFATc1. Bcl6-overexpression inhibited osteoclastogenesis in vitro, whereas 
Bcl6-deficient mice showed accelerated osteoclast differentiation and severe osteoporosis. 
We report that Bcl6 is a direct target of Blimp1 and that mice lacking Blimp1 in  
osteoclasts exhibit osteopetrosis caused by impaired osteoclastogenesis resulting from  
Bcl6 up-regulation. Indeed, mice doubly mutant in Blimp1 and Bcl6 in osteoclasts exhibited 
decreased bone mass with increased osteoclastogenesis relative to osteoclast-specific 
Blimp1-deficient mice. These results reveal a Blimp1–Bcl6–osteoclastic molecule axis, 
which critically regulates bone homeostasis by controlling osteoclastogenesis and may 
provide a molecular basis for novel therapeutic strategies.
© 2010 Miyauchi et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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Shinohara et al., 2008). To identify genes potentially sup­
pressed after RANKL stimulation of osteoclast precursor cells 
(BM macrophages [BMMs]), we undertook comparative   
microarray screens of BMMs treated with or without RANKL 
and found that expression of the transcriptional repressor Bcl6 
was down­regulated by RANKL (Fig. 1 A). Bcl6 down­ 
regulation by RANKL was confirmed by real­time RT­PCR, 
immunofluorescence, and immunoblot analysis (Fig. S1 and 
Fig. 1 B). Immunofluorescence analysis showed that Bcl6 was 
detected in the nuclei of M­CSF–dependent macrophages, 
but not in nuclei of multinuclear osteoclasts induced by 
RANKL (Fig. 1 B). Interestingly, chromatin immunoprecip­
itation (ChIP) assays showed that, in the absence of RANKL, 
Bcl6 was recruited to the NFATc1 P1 promoter, a region 
critical for regulating NFATc1 expression in osteoclasts, and 
was dismissed from the promoter after RANKL treatment. In 
contrast, NFATc1, an essential positive regulator of osteo­
clastogenesis, was absent from the NFATc1 P1 promoter in 
the absence of RANKL, but recruited after RANKL stimula­
tion (Fig. 1 C). These results suggest a potential role of Bcl6 
in inhibiting osteoclastogenesis. Bcl6 overexpression also   
potently inhibited osteoclast differentiation in vitro (Fig. 1 D), 
suggesting that Bcl6 negatively regulates osteoclast differenti­
ation and that its down­regulation after RANKL stimulation 
is critical to induce osteoclastogenesis.
Bcl6 deficiency facilitates osteoclast formation
To characterize the physiological roles of Bcl6 in osteoclasto­
genesis, we analyzed Bcl6­deficient (Bcl6/) mice. Bcl6/ 
mice exhibited lower bone mass as detected by microradio­
graphical  and  dual­energy  x­ray  absorptiometry  analysis 
compared with heterozygous littermates (Bcl6+/; Fig. 2, 
A and B). Consistently, histomorphometric analysis of Bcl6/ 
mice demonstrated increased osteoclastogenesis and large   
osteoclast formation in Bcl6/ mice. Bcl6/ mice also showed 
elevated levels of serum C­terminal telopeptides of type I 
collagen (CTx) and decreased bone parameters (Fig. 2, C and 
D, and Fig. S2). In vitro, osteoclast progenitor cells isolated 
from Bcl6­deficient mice and treated with RANKL differen­
tiated more rapidly into multinuclear tartrate­resistant acid 
phosphatase (TRAP)–positive cells than did those from con­
trol mice (Fig. 2 E and not depicted). Lower concentrations 
of RANKL not sufficient to differentiate control cells induced 
osteoclast differentiation of Bcl6­deficient cells (Fig. 2 E). 
Furthermore, increased bone resorbing activity was evident 
in Bcl6­deficient osteoclasts (Fig. 2 F), suggesting loss of a 
negative regulator of osteoclast function and differentiation. 
Deletion of Bcl6 in osteoclast precursor cells did not alter cell 
proliferation or induce apoptosis (Fig. S3). Thus, Bcl6 func­
tions to regulate osteoclast differentiation and bone homeo­
stasis, and its down­regulation by RANKL is required for 
osteoclast formation.
Blimp1 regulates Bcl6 expression and osteoclastogenesis
Next, we searched for a factor that might suppress Bcl6   
during osteoclastogenesis and found that the transcriptional 
a transcription factor required for osteoclastogenesis (Takayanagi 
et al., 2002; Koga et al., 2004; Sato et al., 2006; Shinohara et al., 
2008). Activated NFATc1 induces expression of “osteoclastic” 
molecules essential for osteoclast differentiation and func­
tion, such as DC­specific transmembrane protein (DC­STAMP) 
to facilitate cell–cell fusion, cathepsin K (Ctsk) to promote 
bone matrix proteolysis, and NFATc1 to drive differentiation 
(Yagi et al., 2005; Li et al., 2006). Thus, signaling pathways 
mediated by positive regulators of NFATc1 in osteoclasto­
genesis have been intensively studied, whereas factors nega­
tively modulating osteoclastogenesis are largely unknown.
B lymphocyte–induced maturation protein 1 (Blimp1) 
has been investigated in numerous cell types (John and   
Garrett­Sinha, 2009) and is reportedly essential for specifi­
cation and maintenance of primordial germ cells (PGCs) 
through silencing of somatic programs (Ohinata et al., 2005). 
B cell lymphoma 6 (Bcl6) was originally identified as a pro­
tooncogene because its chromosomal translocation and con­
stitutive expression promotes lymphomagenesis (Ohno, 2006). 
Bcl6/ mice show impaired germinal center formation   
(Fukuda et al., 1997). The roles of Blimp1 and Bcl6 have also 
been  investigated  in  B  cell  and  plasma  cell  development 
(Turner et al., 1994; Fukuda et al., 1997), as well as in T cells 
(Dent et al., 1998; Kusam et al., 2003; Ichii et al., 2004; 
Kallies et al., 2006; Martins et al., 2006; Cimmino et al., 
2008). However, the roles of Blimp1 and Bcl6, both of which 
are transcriptional repressors, have not previously been char­
acterized in osteoclastogenesis or skeletal disorders, although 
mutations in Bcl6­associated molecules are reportedly seen in 
skeletal pathologies such as malformation of fingers and clav­
icles (Ng et al., 2004). Recently, it was reported that inhibit­
ing NFATc1 using the NFATc1 inhibitor FK506 actually 
resulted in reduced bone mass caused by inhibition of bone 
formation that was more potent than inhibition of osteoclas­
togenesis (Koga et al., 2005). Therefore, additional regulators 
of osteoclast differentiation have been sought as factors that 
could potentially increase bone mass.
In this study, we identify two transcriptional repressors 
controlling osteoclastogenesis, Bcl6 and Blimp1. We show that 
Bcl6 negatively regulates expression of osteoclastic genes, i.e., 
NFATc1, DC-STAMP, and Ctsk, which are all NFATc1   
targets. We found that Bcl6 is recruited to promoters of these 
genes, and that Bcl6 inhibits osteoclastogenesis. We also report 
that Blimp1 binds to the Bcl6 promoter, likely suppressing its 
expression. Bcl6­deficient mice exhibited decreased bone mass 
with increased osteoclastogenesis, whereas osteoclast­specific 
Blimp1 conditional KO (cKO) mice showed impaired osteo­
clast differentiation and increased bone mass, likely resulting 
from Bcl6 dysregulation. Overall, our data demonstrate that 
an axis of transcriptional repressors is crucial to regulate   
osteoclastogenesis and bone homeostasis.
RESULTS
Bcl6 is a negative regulator of osteoclastogenesis
RANKL stimulates osteoclastogenesis by activating NFATc1 
(Takayanagi et al., 2002; Koga et al., 2004; Sato et al., 2006; JEM VOL. 207, April 12, 2010 
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RANKL,  Blimp1  was  absent  from  the  Bcl6  promoter,   
but was recruited there by RANKL treatment (Fig. S5 B). 
Thus, we conclude that Bcl6 is a direct target of Blimp1   
in osteoclasts.
To investigate physiological roles of Blimp1 in osteoclast 
differentiation, we established osteoclast­specific Blimp1 cKO 
mice (CtskCre/+Blimp1flox/-), as Blimp1­null mice are embry­
onic  lethal  (Vincent  et  al.,  2005).  Blimp1  heterozygotes 
(Blimp1+/) were crossed with Ctsk­Cre mice (CtskCre/+) in 
which Cre is knocked into the Ctsk locus (Nakamura et al., 
2007). Next, CtskCre/+Blimp1+/ mice were crossed with a 
transgenic strain harboring loxP­flanked (floxed) Blimp1 al­
leles (Blimp1flox/flox; Ohinata et al., 2005) to yield Blimp1 cKO 
mice. CtskCre/+Blimp1flox/+ mice served as controls. Blimp1 
cKO mice showed increased trabecular bone mass and an   
expanded growth plate compared with control mice, as 
seen by histomorphometric and microradiographical anal­
ysis (Fig. 3, B–D). TRAP staining of bone sections and anal­
ysis of serum CTx levels demonstrated severe inhibition of 
TRAP­positive osteoclast formation and bone resorbing ac­
tivity, respectively (Fig. 3, E and F). Bone­morphometric 
analysis revealed reduced osteoblastic parameters in Blimp1 
cKO mice (Fig. 3 C). Differentiation of osteoblasts isolated 
from osteoclast­specific Blimp1 cKO mice did not differ 
repressor Blimp1, also called Prdm1, was specifically up­ 
regulated during osteoclast formation (Fig. S4 A). Blimp1 
expression in osteoclasts was also demonstrated by using 
Blimp1­EGFP BAC transgenic mice, in which the EGFP se­
quence is knocked into the Blimp1 locus, and by the observa­
tion  that  TRAP­positive  cells  showed  Blimp1  expression 
(Fig. S4 B). RT­PCR analysis confirmed Blimp1 induction 
in BMMs in the presence of RANKL in parallel with induc­
tion of Ctsk, a marker of osteoclast differentiation (Fig. 3 A). 
To determine whether Bcl6 is a Blimp1 target, an electro­
phoretic mobility shift assay (EMSA) was undertaken using a 
Bcl6 probe corresponding to a Bcl6 regulatory region (Cimmino 
et al., 2008). Blimp1 formed a complex with the probe, but 
not  with  a  Bcl6mut  probe  in  which  two  nucleotides  are 
changed to disrupt the Blimp1 binding sequence (Fig. S5 A). 
The PRDI probe, which corresponds to a region of the inter-
feron  promoter known to bind Blimp1 protein (Keller and 
Maniatis, 1991) weakly but competitively, inhibited complex 
formation of the Bcl6 probe with Blimp1 (Fig. S5 A). In ad­
dition, unlabeled Bcl6 probe competed with labeled Bcl6 
probe–Blimp1 to block complex formation, whereas unla­
beled Bcl6mut probe did not (Fig. S5 A), confirming speci­
ficity  and  suggesting  that  Bcl6  is  a  direct  Blimp1  target. 
Furthermore, ChIP analysis showed that, in the absence of 
Figure 1.  Bcl6 is suppressed during osteoclastogenesis and inhibits osteoclast formation. (A) Bcl6 expression was examined by comparative  
microarray analysis between osteoclast precursors (M-CSF) and osteoclasts (M-CSF + RANKL) cultured for 6 d. (B) BMMs were cultured with or without 
RANKL for 8 d and subjected to immunofluorescence staining (left) and immunoblot (right) for Bcl6. Nuclei were visualized by DAPI. Bar, 25 µm.  
(C) Recruitment of NFATc1 and Bcl6 to the NFATc1 P1 distal promoter was detected by ChIP assay. RAW264.7 cells were stimulated with or without 
RANKL for 48 h and subjected to ChIP analysis. (D) RAW264.7 cells transduced with Bcl6-overexpressing (Bcl6) or mock (control) retrovirus were cultured 
in the presence (RANKL) or absence (control) of RANKL for 5 d and stained with TRAP. Left, TRAP staining. (right) Numbers are means ± SD of multinu-
clear TRAP-positive cells in control or Bcl6-overexpressing RAW264.7 cells cultured with RANKL (**, P < 0.001; n = 6). Representative data of three inde-
pendent experiments are shown (B–D).754 Blimp1–Bcl6 axis influences bone mass | Miyauchi et al.
tion  of  Blimp1  in  osteoclasts  did  not  alter  precursor  cell 
proliferation or induction of apoptosis (Fig. S7, A and B). 
Furthermore, immune cell populations such as CD3­, B220­, 
from  that  seen  in  control  mice  (Fig.  S6),  suggesting  that 
Blimp1 deficiency in osteoclast progenitor cells promotes de­
creased osteoblast differentiation and bone formation. Dele­
Figure 2.  Increased osteoclast formation resulting from Bcl6 deficiency. (A) Micro focus CT analysis of femurs of Bcl6+/ (left) and Bcl6/ (right) 
mice. (B) Bone mineral density (BMD) of equal longitudinal division of femurs of Bcl6+/ (open circles) and Bcl6/ (closed circles) mice. Data are mean 
BMD (mg/cm2) ± SD (*, P < 0.05; **, P < 0.01; ***, P < 0.001; n = 3). (C) TRAP staining of tibial sections of Bcl6+/ (top) and Bcl6/ (bottom) mice, and 
osteoclast surface as a percentage of bone surface (OcS/BS). Data are means ± SD (**, P < 0.001; n = 5). (D) Serum levels of C-terminal teropeptides of 
type I collagen (CTx) were analyzed in Bcl6+/ (white bar) and Bcl6/ (shaded bar) mice. Data are means ± SD (**, P < 0.001; n = 3). (E) Osteoclast precur-
sor cells from control (Bcl6+/) or Bcl6/ mice were cultured in the presence or absence of RANKL for 5 d and subjected to May-Grünwald Giemsa and 
TRAP staining, and the number of multinuclear TRAP-positive cells containing more than three nuclei was determined. Data are means ± SD of cells  
containing more than three nuclei (**, P < 0.001; n = 3). (F) Bone resorbing activity in Bcl6+/ (top) and Bcl6/ (bottom) osteoclasts was analyzed by a  
pit formation assay. Representatives of at least three (E) and two (F) independent experiments are shown. Bars: (A) 1 mm; (C, E, and F) 100 µm.JEM VOL. 207, April 12, 2010 
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was significantly up­regulated in the presence of RANKL 
in control cells; however, Blimp1 induction was significantly 
inhibited in Blimp1 cKO cells (Fig. 4 C). In contrast, Bcl6 
expression was significantly down­regulated in control cells 
in the presence of RANKL; however, Bcl6 expression in 
Blimp1 cKO cells was significantly up­regulated in Blimp1 
cKO cells, even in the presence of RANKL (Fig. 4, C and D), 
Mac1­, or Gr1­positive cells were normal in the Blimp1 osteo­
clast­specific KO, suggesting that Blimp1 is required to regu­
late osteoclast differentiation and bone homeostasis (Fig. S8).
Severe inhibition of osteoclastogenesis was also observed 
in in vitro culture. Multinuclear TRAP­positive osteoclast 
formation induced by RANKL was significantly inhibited   
in Blimp1 cKO cells (Fig. 4, A and B). Blimp1 expression 
Figure 3.  Blimp1 is essential for osteoclastogenesis and regulates bone homeostasis. (A) Total RNA isolated from BMMs cultured with M-CSF and 
RANKL for indicated periods was subjected to RT-PCR analysis with primers specific for Blimp1 (top), Ctsk (middle), and -actin (bottom). Representatives 
of at least three independent experiments are shown. (B–F) Bone phenotypes of osteoclast-specific Blimp1 KO (Blimp1 cKO) female mice at 8 wk old.  
(B) Longitudinal sections of tibias of control mice (Ctl; left) and Blimp1 cKO mice (right) were stained by toluidine blue. (C) Bone parameters are shown. 
Data are mean bone volume per total volume (BV/TV; %), trabecular number (Tb. N; /mm), osteoblast surface per bone surface (Ob.S/BS; %), or bone for-
mation rate per bone surface (BFR/BS; mm3/cm2/y) ± SD of control (Ctl; white bar) and Blimp1 cKO (cKO; shaded bar) mice (*, P < 0.01; n = 5). (D) Micro-
focus CT analysis of femurs of control mice (Ctl; left) and Blimp1 cKO mice (right). (E) TRAP staining of tibial sections of control mice (Ctl; left) and Blimp1 
cKO mice (right). Osteoclast parameters are shown as mean osteoclast number per bone perimeter (N.Oc/B.Pm) or osteoclast surface per bone surface  
(Oc.S/BS.) ± SD of control (Ctl; white bar) and Blimp1 cKO (cKO; shaded bar) mice (n = 5). (F) Serum CTx levels as a marker of bone resorption of control 
(Ctl; white bar) and Blimp1 cKO (cKO; shaded bar) mice (*, P < 0.01; n = 5). Bars: (B and E) 100 µm; (D) 1 mm.756 Blimp1–Bcl6 axis influences bone mass | Miyauchi et al.
NFATc1 (Matsumoto et al., 2004; Asagiri et al., 2005; Yagi 
et al., 2007), was markedly inhibited in Blimp1 cKO osteo­
clasts (Fig. 5 A). It was shown by ChIP analysis that NFATc1 
was not evident on osteoclastic gene promoters without 
RANKL, but was recruited there after RANKL treatment of 
control cells (Fig. 5 B). In contrast, in the absence of RANKL, 
Bcl6 was present on osteoclastic gene promoters, but was lost 
from those promoters after RANKL treatment of control 
suggesting that Blimp1 is critical to suppress Bcl6 expression 
in osteoclasts during differentiation by RANKL and is essen­
tial for regulating osteoclastogenesis.
Bcl6 suppresses NFATc1 target genes during 
osteoclastogenesis
Expression  of  genes  encoding  osteoclastic  factors,  such  as 
NFATc1, DC-STAMP, and Ctsk, all of which are targets of 
Figure 4.  Impaired osteoclastogenesis and Bcl6 expression resulting from Blimp1 deficiency. (A–C) BMMs from control (Ctl) or Blimp1 cKO (cKO) 
mice were cultured in the presence or absence of RANKL for 8 d. Cells were then subjected to May-Grünwald Giemsa and TRAP staining (A), the number 
of TRAP-positive cells containing more than three nuclei was scored (B, left), and the number of nuclei in each multinuclear osteoclast was determined  
(B, right). Bar, 100 µm. Numbers are means ± SD of multinuclear cells (**, P < 0.001; n = 3). (C) Total RNA was prepared from control (white bars) or 
Blimp1 cKO (shaded bars) cells treated with (+) or without () RANKL, and Blimp1 (left) or Bcl6 (right) expression relative to -actin was analyzed by 
quantitative real-time PCR. Data represent means ± SD of Blimp1/-actin or Bcl6/-actin levels (**, P < 0.001; n = 4). (D) Whole-cell lysates from control 
or Blimp1 cKO cells cultured with M-CSF alone or M-CSF plus RANKL were analyzed by immunoblotting to detect Blimp1, Bcl6, and NFATc1. Actin was 
analyzed as an internal control. Representatives of at least four independent experiments are shown.JEM VOL. 207, April 12, 2010 
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DKO mice showed accelerated osteoclastogenesis compared 
with those from Blimp1 cKO mice (Fig. 6, B and C), sug­
gesting  that  Blimp1  regulates  osteoclastogenesis  in  part 
through  controlling  Bcl6.  These  results  reveal  that  the 
Blimp1–Bcl6–osteoclastic molecule axis is critical for control­
ling osteoclast differentiation and bone homeostasis (Fig. 7).
DISCUSSION
Here, we show that two transcriptional repressors, Bcl6 and 
Blimp1, are essential to control physiological osteoclast de­
velopment and maintenance of bone homeostasis. Bcl6, a 
member of the POZ/BTB­zinc finger protein family, sup­
presses expression of “osteoclastic” genes, all of which are 
targets of NFATc1 (Matsumoto et al., 2004; Asagiri et al., 
2005; Yagi et al., 2007), thereby antagonizing NFATc1 func­
tion. Indeed, NFATc1 deficiency in osteoclasts results in   
impaired differentiation (Asagiri et al., 2005), whereas Bcl6­
deficient mice exhibit accelerated osteoclast formation and 
decreased bone mass. Blimp1, encoded by Prdm1, acts as a 
suppressor of Bcl6, likely by direct binding to the Bcl6 pro­
moter. In contrast to Bcl6­deficient mice, osteoclast­specific 
Blimp1 cKO mice display impaired osteoclast differentiation 
and increased bone mass. Expression of Bcl6 and Blimp1 is re­
ciprocal in normal osteoclast formation, and unusual elevation 
cells (Fig. 5 B). These data strongly indicate that NFATc1 
and Bcl6 are reciprocally recruited to osteoclastic gene pro­
moters. Significantly, reciprocal recruitment of NFATc1 and 
Bcl6 was severely impaired in Blimp1 cKO cells (Fig. 5 B), 
suggesting that Blimp1 up­regulation is critical for loss of 
Bcl6 from osteoclastic promoters after RANKL stimulation. 
Bcl6 was not present on the NFATc2 promoter, which is not 
activated by RANKL stimulation (Asagiri et al., 2005), in the 
presence or absence of RANKL (Fig. 5 B), suggesting that 
Bcl6 is selectively recruited to promoters of osteoclastic genes 
and inhibits osteoclast differentiation. Whereas Bcl6 was 
down­regulated by RANKL treatment in control cells, Bcl6 
expression was maintained in Blimp1 cKO cells, even in the 
presence of RANKL (Fig. 4 C and Fig. S9). These data indi­
cate that impaired Bcl6 down­regulation caused by loss of 
Blimp1 results in continuous inhibition of osteoclastic gene 
expression, which in turn promotes severe inhibition of   
osteoclastogenesis and increased bone mass.
Finally, to confirm the role of Blimp1 in regulating osteo­
clastogenesis through Bcl6, osteoclast­specific Blimp1/Bcl6 
double KO mice (double KO [DKO]; CtskCre/+Blimp1flox/-
Bcl6/ mice) were established (Fig. 6). DKO mice exhibited 
decreased bone mass in vivo compared with Blimp1 cKO 
mice (Fig. 6 A). Similarly, progenitor cells isolated from 
Figure 5.  Bcl6 suppresses osteoclast differentiation. (A) Total RNA was prepared from control (white bars) or Blimp1 cKO (shaded bars) cells treated 
with (+) or without () RANKL, and the expression of the osteoclastic genes NFATc1, DC-STAMP, and Ctsk relative to -actin was analyzed by a quantita-
tive real-time PCR. Data are means ± SD of osteoclastic genes/-actin. (**, P < 0.001; n = 4). (B) Recruitment of NFATc1 and Bcl6 to promoters of  
osteoclastic genes such as NFATc1, DC-STAMP, Ctsk, or a negative control gene NFATc2 was analyzed by a ChIP assay. Representatives of at least four  
(A) or two (B) independent experiments are shown.758 Blimp1–Bcl6 axis influences bone mass | Miyauchi et al.
Figure 6.  Bcl6 is a target of Blimp1 during osteoclastogenesis. (A) Bone mineral density (BMD) of equal longitudinal division of femurs of control 
(filled circles), Blimp1 cKO (open circles), and Blimp1 cKO/Bcl6 KO (DKO; filled triangles) mice. Data represent mean BMD (n = 4). (B and C) Osteoclast pro-
genitor cells from control, Blimp1 cKO or DKO mice were cultured in the presence of M-CSF alone or M-CSF plus RANKL for 8 d. Cells were then subjected 
to May-Grünwald Giemsa and TRAP staining (B), and the number of TRAP-positive cells containing more than three nuclei was scored (C). Results are 
representative of three independent experiments. Bar, 100 µm.JEM VOL. 207, April 12, 2010 
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(Baron et al., 2002; Ohno, 2006). Blimp1 also functions in 
specification of the germ cell lineage and acts as a tumor sup­
pressor (Ohinata et al., 2005; John and Garrett­Sinha, 2009). 
Here, we show that Bcl6 and Blimp1, which are both impli­
cated in B cell and T cell development (Turner et al., 1994; 
Fukuda et al., 1997; Dent et al., 1998; Kusam et al., 2003; 
Ichii et al., 2004; Kallies et al., 2006; Martins et al., 2006; 
Cimmino et al., 2008), have a novel function in regulating 
osteoclastogenesis and maintenance of bone homeostasis. It 
has been reported that Blimp1 represses Bcl6 (Cimmino et al., 
2008) or that Blimp1 and Bcl6 regulate each other (Shapiro­
Shelef and Calame, 2005). Blimp1 expression was reportedly 
inhibited by Bcl6 (Martins et al., 2006); however, we did not 
detect dysregulation of Blimp1 expression in Bcl6­deficient 
osteoclasts (unpublished data). Osteoclast­specific Blimp1/
Bcl6 DKO mice exhibited increased osteoclastogenesis with 
decreased bone mass compared with Blimp1 cKO mice, in­
dicating that Blimp1 regulates Bcl6 in osteoclasts. However, 
although Bcl6­deficient cells showed accelerated osteoclasto­
genesis compared with control cells, DKO cells showed   
decreased osteoclast differentiation compared with control 
cells, suggesting that Blimp1 regulates osteoclastogenesis 
through Bcl6 along with other target molecules. Blimp1 has 
multiple targets in lymphocytes and PGCs (Shaffer et al., 2002; 
Kurimoto et al., 2008), and thus it is possible that Blimp1 has 
multiple targets in osteoclasts as well. In osteoclasts, several 
negative regulators for osteoclastogenesis, such as Id, Mafb, and 
Irf8, have been identified (Lee et al., 2006; Kim et al., 2007; 
Zhao et al., 2009). Blimp1 may also target these molecules in 
osteoclasts to stimulate osteoclast differentiation. Further in­
vestigations are needed to clarify the molecular mechanisms of 
the regulation of osteoclastogenesis by Blimp1.
We  used  CtskCre/+  mice  to  establish  osteoclast­specific 
Blimp1 cKO mice because CtskCre/+ mice have been used to 
generate osteoclast­specific KOs of factors such as the estro­
gen receptor and Bcl­XL (Nakamura et al., 2007; Iwasawa et al., 
2009). Osteoclastogenesis, including Ctsk expression, has been 
evaluated in osteoclast­specific gene­targeted cells (Nakamura 
et al., 2007). Blimp1 expression is induced earlier than Ctsk 
(Fig. 3 A), and osteoclastogenesis is inhibited in Blimp1 cKO 
cells, suggesting that continuous Blimp1 expression is re­
quired for full osteoclast differentiation under control of 
RANKL. Blimp1 is also known to be induced by BMP4 and 
LIF in PGCs, where it functions as a transcriptional repressor 
(Ohinata et al., 2009). In osteoclasts, Blimp1 is induced by 
RANKL and acts to repress Bcl6. Thus, signaling regulating 
Blimp1 expression differs between PGCs and osteoclasts.
Bone homeostasis requires a delicate balance between os­
teoclastic and osteoblastic activities. A decline in bone vol­
ume is closely related to up­regulation of osteoclast activity, 
and thus osteoclasts could be targeted therapeutically to treat 
skeletal disorders such as osteoporosis and destructive bone 
metastasis. FK506, a specific inhibitor of calcineurin­NFATs, 
inhibits osteoclastogenesis, but does not increase bone mass, 
as FK506 also inhibits bone formation (Koga et al., 2005). 
Thus, additional factors that could negatively regulate osteoclast 
of Bcl6 expression caused by Blimp1 deficiency leads to   
osteoclastogenesis failure, as indicated by increased bone mass 
seen in a Blimp1 cKO model. Signals positively regulating 
NFATc1 in osteoclasts, such as TRAF6, c­Fos, ITAM­
PLC­Ca2+ signals, Btk, and Tec (Takayanagi et al., 2002; 
Koga et al., 2004; Shinohara et al., 2008), have been charac­
terized, and NFATc1 reportedly positively autoregulates in 
osteoclasts (Asagiri et al., 2005). However, factors modulat­
ing this activity have not been described. Our study charac­
terizes such an axis of factors that serve as a molecular switch 
to control osteoclastogenesis and bone homeostasis after 
RANKL stimulation.
To date, the skeletal and immune systems have been 
shown to share common molecules to achieve homeostasis 
(Nakashima and Takayanagi, 2008). RANKL and RANK 
were originally identified in T cells and DCs (Anderson et al., 
1997), respectively, and both are essential for osteoclastogen­
esis (Kong et al., 1999; Dougall et al., 1999). NFATc1 was 
identified in T cells and plays an essential role in osteoclast 
formation (Northrop et al., 1994; Asagiri et al., 2005). DC­
STAMP plays a role in DC function and is required for cell–
cell fusion of osteoclasts and macrophage giant cells (Yagi et al., 
2005, 2007; Sawatani et al., 2008). Besides roles in immune 
system, Bcl6 has antiapoptotic and protooncogenic function 
Figure 7.  A schematic model of osteoclastogenesis regulated by 
the Blimp1-Bcl6-osteoclastic gene axis. RANKL–RANK interaction 
results in Blimp1 induction, leading to Bcl6 down-regulation and disso-
ciation of Bcl6 from osteoclastic gene promoters, an event critical for 
osteoclastogenesis. NFATc1 activation is induced by various factors, such 
as ITAM, TRAF6, c-Fos, and Ca2+ signaling, which are also activated  
by RANKL.760 Blimp1–Bcl6 axis influences bone mass | Miyauchi et al.
serially diluted products using the same PCR reactions. -actin expression 
served as an internal control. Primer sequences were as follows: -actin for­
ward: 5­TGAGAGGGAAATCGTGCGTGAC­3; -actin reverse: 5­AA­
GAAGGAAGGCTGGAAAAGAG­3;  Bcl6 forward: 5­AGACGCACAGT­
GACAAACCATACAA­3; Bcl6 reverse: 5­GCTCCACAAATGTTACA­
GCGATAGG­3; Blimp1 forward: 5­TTCTTGTGTGGTATTGTCGGGA­
CTT­3; Blimp1 reverse: 5­TTGGGGACACTCTTTGGGTAGAGTT­3; 
Ctsk  forward:  5­ACGGAGGCATTGACTCTGAAGATG­3;  Ctsk  
reverse: 5­GGAAGCACCAACGAGAGGAGAAAT­3; DC-STAMP for­
ward: 5­TCCTCCATGAACAAACAGTTCCAA­3; DC-STAMP re­
verse: 5­AGACGTGGTTTAGGAATGCAGCTC­3; NFATc1 forward: 
5­CAAGTCTCACCACAGGGCTCACTA­3; NFATc1 reverse: 5­GCG­
TGAGAGGTTCATTCTCCAAGT­3; type I collagen forward: 5­CCTGG­
TAAAGATGGTGCC­3; type I collagen reverse: 5­CACCAGGTTCAC­
CTTTCGCACC­3; osteocalcin forward: 5­TAGCAGACACCATGAGGA­
CCCT­3; osteocalcin reverse: 5­TGGACATGAAGGCTTTGTCAGA­3.
Immunofluoresence. Cells were fixed with 4% paraformaldehyde (Wako 
Pure Chemical Industries) in PBS solution for 15 min at room temperature. 
After washing to remove fixation solution, cells were permeabilized in PBS 
containing 0.1% Triton X­100 for 10 min at room temperature and then 
washed. Nonspecific antibody binding was blocked by treatment with 5% 
BSA (Sigma­Aldrich Co.) in PBS. Cells were then stained with anti­Bcl6 
antibody (1:50 dilution, N­3; Santa Cruz Biotechnology, Inc.) at 4°C over­
night, washed with PBS and stained with Alexa Fluor 546–conjugated anti­
rabbit IgG antibody (1:200 dilution) for 1 h at room temperature. Cells were 
washed to remove secondary antibody and incubated with DAPI solution 
(Dojindo Co.; 1:5,000) for nuclear staining, followed by microscopic obser­
vation (model BZ­9000; Keyence Co).
Immunoblotting analysis. Whole­cell lysates were prepared from BM 
cultures using RIPA buffer (1% Triton X­100, 1% sodium deoxycholate, 
0.1% SDS, 150 mM NaCl, 10 mM Tris­HCl, pH 7.5, 5 mM EDTA, and a 
protease inhibitor cocktail; Sigma­Aldrich). Equivalent amounts of protein 
were separated by SDS­PAGE and transferred to a PVDF membrane (Millipore). 
Proteins were detected using the following antibodies: anti­NFATc1 (7A6), 
anti­Blimp1 (6D3), anti­Bcl6 (N­3) (Santa Cruz Biotechnology, Inc.), and 
anti­actin (A2066; Sigma­Aldrich).
EMSA. Nuclear extracts were prepared from COS7 cells transfected with 
pCAG­HA­Blimp1 or pCAG. Each extract was incubated for 30 min on ice 
with a [32P]labeled probe in binding buffer (10 mM Tris­HCl, pH 7.9, 50 mM 
NaCl, 0.5 mM EDTA, 1 mM DTT, and 10% glycerol) containing 2 µg of 
poly(dI­dC), KCl, and BSA. Complexes were separated on 5% polyacryl­
amide gels in TGE buffer (25 mM Tris­HCl, 190 mM glycine, and 1 mM 
EDTA). The Bcl6 probe corresponding to a putative Blimp1 binding site in 
the Bcl6 gene was 5­AGGTTTCATAGGAAGTGAAAACCCTGCTAT­3. 
A mutated probe (underlined residues) served as a negative control (Bcl6mut 
probe;  5­AGGTTTCATAGGAAGTTAGAACCCTGCTAT­3).  After 
electrophoresis, gels were dried and exposed to the imaging plate, and signals 
were analyzed using ImageGauge software on the BAS2000 image ana­
lyzer (Fuji Film Co.).
ChIP. ChIP was performed on osteoclasts. M­CSF–induced BMMs were 
cultured on 100­mm type I collagen­coated culture dishes (Asahi Glass Co.) 
with  M­CSF and  recombinant RANKL  for  the indicated  time  periods, 
and then subjected to ChIP analysis using the ChIP­IT Enzymatic kit   
(ActivMotif Inc.), according to the manufacturer’s instructions. Immuno­
precipitation was performed using anti­NFATc1 (7A6), anti­Bcl6 (N­3), 
and anti­Blimp1 (C14A4; Cell Signaling Technology). DNA was pu­
rified by QIAquick PCR purification kit (QIAGEN) and analyzed using 
primers corresponding to the following promoters: NFATc1­P1 promoter, 
5­CCGGGACGCCCATGCAATCTGTTAGTAATT­3  (sense)  and   
5­GCGGGTGCCCTGAGAAAGCTACTCTCCCTT­3 (antisense); the 
DC-STAMP promoter, 5­GGGGGTCCTCATTTCTACAACTCAT­3  
differentiation, such as those identified here, have been 
sought. Thus, our study provides new insight into regulation 
of osteoclastogenesis and bone homeostasis and forms the   
basis for developing novel therapeutic approaches to treat 
skeletal disorders.
MATERIALS AND METHODS
Mice. Bcl6/ mice on a mixed C57BL/6 X 129/Sv background were gen­
erated by crossing Bcl6 heterozygotes (Bcl6+/; Fukuda et al., 1997). Osteo­
clast­specific Blimp1 cKO mice on a C57BL/6 background were generated 
from three lines: mice carrying loxP­flanked Blimp1 alleles (Blimp1flox/flox; 
Ohinata et al., 2005), mice harboring Cre in the Ctsk (CtskCre/) locus   
(Nakamura et al., 2007), and Blimp1 heterozygotes (Blimp1+/; provided by 
A. Tarakhovsky, The Rockefeller University, New York, NY). Animals 
were maintained under specific pathogen–free conditions in animal facilities 
certified by the Keio University School of Medicine animal care committee. 
Animal protocols were approved by the Keio University School of Medicine 
animal care committee.
In vitro osteoclast formation. BM cells isolated from long bones (femurs, 
tibias, and humerus) were cultured 72 h in MEM (Sigma­Aldrich) contain­
ing 10% heat­inactivated FBS (JRH Biosciences) and GlutaMax supple­
mented with M­CSF (50 ng/ml; Kyowa Hakko Kirin Co.). Adherent cells 
were then collected for analysis. 105 cells were cultured with M­CSF and   
recombinant soluble RANKL (25 ng/ml; PeproTech Ltd.) for indicated 
time periods. Mouse spleen cells were cultured overnight in MEM con­
taining 10% heat­inactivated FBS and GlutaMax supplemented with M­CSF. 
After this incubation, nonadherent cells were collected and 105 cells were 
cultured with M­CSF and recombinant soluble RANKL (5 or 25 ng/ml) for 
the indicated time periods. Osteoclastogenesis was evaluated by TRAP and 
May­Grünwald Giemsa staining (Miyamoto et al., 2000; Yagi et al., 2005). 
RAW264.7 cells were maintained in MEM containing 10% heat­inactivated 
FBS and GlutaMax and stimulated by recombinant soluble RANKL to   
induce osteoclast formation.
Pit formation assay. Bone resorbing activity of osteoclasts was analyzed   
as previously described (Iwamoto et al., 2004). In brief, osteoclast precursors 
isolated from indicated mice were seeded on dentin slices and cultured in 
the presence of M­CSF plus RANKL for 6 d. Dentin slices were then 
stained by toluidine blue and observed under a microscope (model BZ­9000; 
Keyence Co.).
Analysis of skeletal morphology. Bcl6/, DKO, and control littermates 
were necropsied 16 d after birth. Hindlimbs were removed, fixed with 70% 
ethanol, and subjected to dual­energy x­ray absorptiometry analysis to mea­
sure bone mineral density and for bone­histomorphometric analysis. Female 
8­wk­old Blimp1 cKO mice and control littermates were administered   
intraperitoneal injections of 16 mg/kg calcein (Dojindo Co.) at 6 and 1 d 
before sacrifice to evaluate bone formation rate. Hindlimbs were removed 
and analyzed as described above.
ELISA. Serum levels of osteocalcin and C­terminal telopeptides of type I col­
lagen (CTx) were measured by the Mouse Osteocalcin EIA kit (Biomedical 
Technologies Inc.) and RatLaps EIA (Immunodiagnostics Systems Ltd.), re­
spectively. Assays were undertaken following the manufacturers’ instructions.
Real-time PCR analysis. Total RNAs were isolated from BM cultures by 
TRIzol reagent (Invitrogen). After denaturation of total RNAs at 70°C for 
5 min, cDNAs were synthesized from total RNAs using oligo(dT) primer 
and  reverse  transcription  (Wako  Pure  Chemicals  Industries).  Real­time 
PCR was performed using SYBR Premix ExTaq II (Takara Bio Inc.) with 
the DICE Thermal cycler (Takara Bio Inc.), according to the manufacturer’s 
instructions. Samples were matched to a standard curve generated by amplifying JEM VOL. 207, April 12, 2010 
Article
761
Dougall, W.C., M. Glaccum, K. Charrier, K. Rohrbach, K. Brasel, T. De 
Smedt, E. Daro, J. Smith, M.E. Tometsko, C.R. Maliszewski, et al. 
1999. RANK is essential for osteoclast and lymph node development. 
Genes Dev. 13:2412–2424. doi:10.1101/gad.13.18.2412
Fukuda,  T.,  T.  Yoshida,  S.  Okada,  M.  Hatano,  T.  Miki,  K.  Ishibashi,   
S. Okabe, H. Koseki, S. Hirosawa, M. Taniguchi, et al. 1997. Disruption 
of the Bcl6 gene results in an impaired germinal center formation. J. Exp.   
Med. 186:439–448. doi:10.1084/jem.186.3.439
Ichii, H., A. Sakamoto, Y. Kuroda, and T. Tokuhisa. 2004. Bcl6 acts as an 
amplifier for the generation and proliferative capacity of central memory 
CD8+ T cells. J. Immunol. 173:883–891.
Iwamoto, K., T. Miyamoto, N. Hosogane, I. Hamaguchi, M. Takami, K. 
Takagi, and T. Suda. 2004. Dimer formation of receptor activator of 
nuclear factor kappa B induces incomplete osteoclast formation. Biochem. 
Biophys. Res. Commun. 325:229–234. doi:10.1016/j.bbrc.2004.10.024
Iwasawa, M., T. Miyazaki, Y. Nagase, T. Akiyama, Y. Kadono, M. Nakamura,   
Y. Oshima, T. Yasui, T. Matsumoto, T. Nakamura, et al. 2009. The 
antiapoptotic protein Bcl­xL negatively regulates the bone­resorbing 
activity of osteoclasts in mice. J. Clin. Invest. 119:3149–3159.
John, S.A., and L.A. Garrett­Sinha. 2009. Blimp1: a conserved transcrip­
tional repressor critical for differentiation of many tissues. Exp. Cell Res. 
315:1077–1084. doi:10.1016/j.yexcr.2008.11.015
Kallies,  A.,  E.D.  Hawkins,  G.T.  Belz,  D.  Metcalf,  M.  Hommel,  L.M. 
Corcoran, P.D. Hodgkin, and S.L. Nutt. 2006. Transcriptional repres­
sor Blimp­1 is essential for T cell homeostasis and self­tolerance. Nat. 
Immunol. 7:466–474. doi:10.1038/ni1321
Karsenty, G., and E.F. Wagner. 2002. Reaching a genetic and molecular 
understanding of skeletal development. Dev. Cell. 2:389–406. doi:10.1016/ 
S1534­5807(02)00157­0
Keller, A.D., and T. Maniatis. 1991. Identification and characterization of a 
novel repressor of beta­interferon gene expression. Genes Dev. 5:868–
879. doi:10.1101/gad.5.5.868
Kim, K., J.H. Kim, J. Lee, H.M. Jin, H. Kook, K.K. Kim, S.Y. Lee, and N. Kim. 
2007. MafB negatively regulates RANKL­mediated osteoclast differen­
tiation. Blood. 109:3253–3259. doi:10.1182/blood­2006­09­048249
Koga, T., M. Inui, K. Inoue, S. Kim, A. Suematsu, E. Kobayashi, T. Iwata, 
H. Ohnishi, T. Matozaki, T. Kodama, et al. 2004. Costimulatory sig­
nals mediated by the ITAM motif cooperate with RANKL for bone   
homeostasis. Nature. 428:758–763. doi:10.1038/nature02444
Koga,  T.,  Y.  Matsui,  M.  Asagiri,  T.  Kodama,  B.  de  Crombrugghe,   
K. Nakashima, and H. Takayanagi. 2005. NFAT and Osterix cooperatively 
regulate bone formation. Nat. Med. 11:880–885. doi:10.1038/nm1270
Kong, Y.Y., H. Yoshida, I. Sarosi, H.L. Tan, E. Timms, C. Capparelli,   
S. Morony, A.J. Oliveira­dos­Santos, G. Van, A. Itie, et al. 1999. OPGL 
is a key regulator of osteoclastogenesis, lymphocyte development and 
lymph­node organogenesis. Nature. 397:315–323. doi:10.1038/16852
Kurimoto, K., Y. Yabuta, Y. Ohinata, M. Shigeta, K. Yamanaka, and   
M. Saitou. 2008. Complex genome­wide transcription dynamics or­
chestrated by Blimp1 for the specification of the germ cell lineage in 
mice. Genes Dev. 22:1617–1635. doi:10.1101/gad.1649908
Kusam,  S.,  L.M.  Toney,  H.  Sato,  and  A.L.  Dent.  2003.  Inhibition  of 
Th2 differentiation and GATA­3 expression by BCL­6. J. Immunol. 
170:2435–2441.
Lee, J., K. Kim, J.H. Kim, H.M. Jin, H.K. Choi, S.H. Lee, H. Kook, K.K. 
Kim, Y. Yokota, S.Y. Lee, et al. 2006. Id helix­loop­helix proteins   
negatively  regulate  TRANCE­mediated  osteoclast  differentiation. 
Blood. 107:2686–2693. doi:10.1182/blood­2005­07­2798
Li, C.Y., K.J. Jepsen, R.J. Majeska, J. Zhang, R. Ni, B.D. Gelb, and M.B. 
Schaffler. 2006. Mice lacking cathepsin K maintain bone remodeling 
but develop bone fragility despite high bone mass. J. Bone Miner. Res. 
21:865–875. doi:10.1359/jbmr.060313
Martins, G.A., L. Cimmino, M. Shapiro­Shelef, M. Szabolcs, A. Herron, E. 
Magnusdottir, and K. Calame. 2006. Transcriptional repressor Blimp­1 
regulates T cell homeostasis and function. Nat. Immunol. 7:457–465. 
doi:10.1038/ni1320
Matsumoto,  M.,  M.  Kogawa,  S.  Wada,  H.  Takayanagi,  M.  Tsujimoto, 
S. Katayama, K. Hisatake, and Y. Nogi. 2004. Essential role of p38   
mitogen­activated protein kinase in cathepsin K gene expression during 
(sense) and 5­GCCACATCACCCTGAATCAATCTT­3 (antisense); the 
Ctsk promoter, 5­CCTTAAACTGGCTCCTGTCAAAGA­3 (sense) and 
5­CCCTTCTTCAGAAGCCCTGTAAT­3  (antisense);  NFATc2  pro­
moter,  5­TTATCAGGGAGCACTGCCCATCTCCGCTTT­3  (sense)   
and  5­CGGTCTGGCCTGAGCGACAGGCCCAGACAA­3  (anti­
sense); and Bcl6 promoter, 5­CAGCCACCCTGAGTTTACAA­3 (sense) 
and 5­CGTTCCAGCACTGTTTTGAA­3 (antisense).
Microarray analysis. BM cells were isolated from 8­wk­old mouse and 
cultured in the presence of M­CSF for 3 d. M­CSF–dependent adherent 
cells were harvested and cultured with M­CSF alone for macrophages and 
M­CSF plus RANKL for osteoclasts, respectively. After 6 days of cultiva­
tion, total RNA was isolated and microarray analysis was undertaken using 
GeneChip Mouse Genome 430 2.0 Array (Affymetrix). Data were analyzed 
using GeneChip Operating Software and deposited in Minimum Informa­
tion about a Microarray Experiment compliant in Gene Expression Omni­
bus (GEO accession no. GSE20850).
Online supplemental material. Fig. S1 shows that Bcl6 is transcription­
ally repressed by RANKL. Fig. S2 shows bone parameters of Bcl6+/ and 
Bcl6/ mice. Fig. S3 shows proliferation and apoptosis of osteoclast precur­
sors from Bcl6+/ and Bcl6/ mice. Fig. S4 shows Blimp1 expression in 
osteoclasts. Fig. S5 shows that Blimp1 binds to the Bcl6 promoter. Fig. S6 
shows normal osteoblastic differentiation in Blimp1 cKO cells. Fig. S7 shows 
proliferation and apoptosis of osteoclast precursors from Blimp1 cKO and 
control mice. Fig. S8 shows immune cell populations in spleens of Blimp1 
cKO and control mice. Fig. S9 shows dysregulation of Bcl6 in Blimp1 
cKO BMM. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20091957/DC1.
We thank Y. Sato for technical support. We thank Prof. T. Kitamura (University of 
Tokyo) and Prof. A. Tarakhovsky (Rockefeller University) for providing retroviral 
vectors and Blimp1+/ mice, respectively.
T. Miyamoto was supported by a grant-in-aid for Young Scientists, Precursory 
Research for Embryonic Science and Technology (PREST), the Uehara memorial 
foundation, Takeda Science Foundation, The Nakatomi Foundation, and Keio 
Kanrinmaru project, Japan. Y. Miyauchi was supported by a grant-in-aid for Young 
Scientists.
The authors have no conflicting financial interests.
Submitted: 8 September 2009
Accepted: 10 March 2010
REFERENCES
Anderson, D.M., E. Maraskovsky, W.L. Billingsley, W.C. Dougall, M.E. 
Tometsko, E.R. Roux, M.C. Teepe, R.F. DuBose, D. Cosman, and 
L. Galibert. 1997. A homologue of the TNF receptor and its ligand   
enhance T­cell growth and dendritic­cell function. Nature. 390:175–
179. doi:10.1038/36593
Asagiri,  M.,  K.  Sato,  T.  Usami,  S.  Ochi,  H.  Nishina,  H.  Yoshida,  I. 
Morita,  E.F.  Wagner,  T.W.  Mak,  E.  Serfling,  and  H.  Takayanagi. 
2005. Autoamplification of NFATc1 expression determines its essential 
role in bone homeostasis. J. Exp. Med. 202:1261–1269. doi:10.1084/ 
jem.20051150
Baron, B.W., J. Anastasi, M.J. Thirman, Y. Furukawa, S. Fears, D.C. Kim, F. 
Simone, M. Birkenbach, A. Montag, A. Sadhu, et al. 2002. The human 
programmed cell death­2 (PDCD2) gene is a target of BCL6 repression: 
implications for a role of BCL6 in the down­regulation of apoptosis. Proc. 
Natl. Acad. Sci. USA. 99:2860–2865. doi:10.1073/pnas.042702599
Cimmino, L., G.A. Martins, J. Liao, E. Magnusdottir, G. Grunig, R.K. 
Perez,  and  K.L.  Calame.  2008.  Blimp­1  attenuates  Th1  differentia­
tion by repression of ifng, tbx21, and bcl6 gene expression. J. Immunol. 
181:2338–2347.
Dent, A.L., J. Hu­Li, W.E. Paul, and L.M. Staudt. 1998. T helper type 2   
inflammatory disease in the absence of interleukin 4 and transcription   
factor STAT6. Proc. Natl. Acad. Sci. USA. 95:13823–13828. doi:10.1073/ 
pnas.95.23.13823762 Blimp1–Bcl6 axis influences bone mass | Miyauchi et al.
osteoclastogenesis through association of NFATc1 and PU.1. J. Biol. 
Chem. 279:45969–45979. doi:10.1074/jbc.M408795200
Miyamoto,  T.,  F.  Arai,  O.  Ohneda,  K.  Takagi,  D.M.  Anderson,  and   
T. Suda. 2000. An adherent condition is required for formation of mul­
tinuclear osteoclasts in the presence of macrophage colony­stimulating 
factor and receptor activator of nuclear factor kappa B ligand. Blood. 
96:4335–4343.
Nakamura, T., Y. Imai, T. Matsumoto, S. Sato, K. Takeuchi, K. Igarashi, Y. 
Harada, Y. Azuma, A. Krust, Y. Yamamoto, et al. 2007. Estrogen pre­
vents bone loss via estrogen receptor alpha and induction of Fas ligand   
in osteoclasts. Cell. 130:811–823. doi:10.1016/j.cell.2007.07.025
Nakashima, T., and H. Takayanagi. 2008. The dynamic interplay between 
osteoclasts and the immune system. Arch. Biochem. Biophys. 473:166–
171. doi:10.1016/j.abb.2008.04.004
Ng,  D.,  N.  Thakker,  C.M.  Corcoran,  D.  Donnai,  R.  Perveen,  A. 
Schneider, D.W. Hadley, C. Tifft, L. Zhang, A.O. Wilkie, et al. 2004. 
Oculofaciocardiodental  and  Lenz  microphthalmia  syndromes  result 
from distinct classes of mutations in BCOR. Nat. Genet. 36:411–416. 
doi:10.1038/ng1321
Northrop, J.P., S.N. Ho, L. Chen, D.J. Thomas, L.A. Timmerman, G.P. 
Nolan,  A.  Admon,  and  G.R.  Crabtree.  1994.  NF­AT  components   
define a family of transcription factors targeted in T­cell activation. 
Nature. 369:497–502. doi:10.1038/369497a0
Ohinata, Y., B. Payer, D. O’Carroll, K. Ancelin, Y. Ono, M. Sano, S.C. 
Barton, T. Obukhanych, M. Nussenzweig, A. Tarakhovsky, et al. 2005. 
Blimp1 is a critical determinant of the germ cell lineage in mice. Nature. 
436:207–213. doi:10.1038/nature03813
Ohinata, Y., H. Ohta, M. Shigeta, K. Yamanaka, T. Wakayama, and M. 
Saitou. 2009. A signaling principle for the specification of the germ cell 
lineage in mice. Cell. 137:571–584. doi:10.1016/j.cell.2009.03.014
Ohno, H. 2006. Pathogenetic and clinical implications of non­immuno­
globulin; BCL6 translocations in B­cell non­Hodgkin’s lymphoma.  
J. Clin. Exp. Hematop. 46:43–53. doi:10.3960/jslrt.46.43
Rodan, G.A., and T.J. Martin. 2000. Therapeutic approaches to bone dis­
eases. Science. 289:1508–1514. doi:10.1126/science.289.5484.1508
Sato, K., A. Suematsu, T. Nakashima, S. Takemoto­Kimura, K. Aoki, Y. 
Morishita, H. Asahara, K. Ohya, A. Yamaguchi, T. Takai, et al. 2006. 
Regulation of osteoclast differentiation and function by the CaMK­
CREB pathway. Nat. Med. 12:1410–1416. doi:10.1038/nm1515
Sawatani, Y., T. Miyamoto, S. Nagai, M. Maruya, J. Imai, K. Miyamoto, 
N. Fujita, K. Ninomiya, T. Suzuki, R. Iwasaki, et al. 2008. The role of 
DC­STAMP in maintenance of immune tolerance through regulation 
of dendritic cell function. Int. Immunol. 20:1259–1268. doi:10.1093/ 
intimm/dxn082
Shaffer,  A.L.,  K.I.  Lin,  T.C.  Kuo,  X.  Yu,  E.M.  Hurt,  A.  Rosenwald, 
J.M.  Giltnane,  L.  Yang,  H.  Zhao,  K.  Calame,  and  L.M.  Staudt. 
2002. Blimp­1 orchestrates plasma cell differentiation by extinguish­
ing the mature B cell gene expression program. Immunity. 17:51–62. 
doi:10.1016/S1074­7613(02)00335­7
Shapiro­Shelef, M., and K. Calame. 2005. Regulation of plasma­cell devel­
opment. Nat. Rev. Immunol. 5:230–242. doi:10.1038/nri1572
Shinohara, M., T. Koga, K. Okamoto, S. Sakaguchi, K. Arai, H. Yasuda,   
T. Takai, T. Kodama, T. Morio, R.S. Geha, et al. 2008. Tyrosine kinases 
Btk and Tec regulate osteoclast differentiation by linking RANK and 
ITAM signals. Cell. 132:794–806. doi:10.1016/j.cell.2007.12.037
Takayanagi, H., S. Kim, T. Koga, H. Nishina, M. Isshiki, H. Yoshida,   
A. Saiura, M. Isobe, T. Yokochi, J. Inoue, et al. 2002. Induction and 
activation of the transcription factor NFATc1 (NFAT2) integrate 
RANKL signaling in terminal differentiation of osteoclasts. Dev. Cell. 
3:889–901. doi:10.1016/S1534­5807(02)00369­6
Turner, C.A. Jr., D.H. Mack, and M.M. Davis. 1994. Blimp­1, a novel zinc   
finger­containing protein that can drive the maturation of B lymphocytes   
into immunoglobulin­secreting cells. Cell. 77:297–306. doi:10.1016/ 
0092­8674(94)90321­2
Vincent, S.D., N.R. Dunn, R. Sciammas, M. Shapiro­Shalef, M.M. Davis, 
K. Calame, E.K. Bikoff, and E.J. Robertson. 2005. The zinc finger 
transcriptional repressor Blimp1/Prdm1 is dispensable for early axis   
formation but is required for specification of primordial germ cells in the 
mouse. Development. 132:1315–1325. doi:10.1242/dev.01711
Yagi, M., T. Miyamoto, Y. Sawatani, K. Iwamoto, N. Hosogane, N. Fujita, 
K. Morita, K. Ninomiya, T. Suzuki, K. Miyamoto, et al. 2005. DC­
STAMP is essential for cell­cell fusion in osteoclasts and foreign body 
giant cells. J. Exp. Med. 202:345–351. doi:10.1084/jem.20050645
Yagi,  M.,  K.  Ninomiya,  N.  Fujita,  T.  Suzuki,  R.  Iwasaki,  K.  Morita,   
N. Hosogane, K. Matsuo, Y. Toyama, T. Suda, and T. Miyamoto. 2007. 
Induction of DC­STAMP by alternative activation and downstream 
signaling mechanisms. J. Bone Miner. Res. 22:992–1001. doi:10.1359/ 
jbmr.070401
Zhao, B., M. Takami, A. Yamada, X. Wang, T. Koga, X. Hu, T. Tamura, 
K. Ozato, Y. Choi, L.B. Ivashkiv, et al. 2009. Interferon regulatory   
factor­8 regulates bone metabolism by suppressing osteoclastogenesis. 
Nat. Med. 15:1066–1071. doi:10.1038/nm.2007